BridGene Biosciences Secures $28 Million Series B+ Funding to Advance TEAD Inhibitor BGC-515 Toward Phase 2
核心洞察
BridGene Biosciences (搜索) completed a $28 million Series B+ financing round led by Bayland Capital (搜索) to advance its lead oncology program BGC-515, a covalent TEAD (搜索) inhibitor for solid tumors.
The funding will support BGC-515's progression through ongoing clinical development toward Phase 2 trials and enable the company's second program to enter clinical testing by 2027.
BridGene leverages its proprietary IMTAC™ chemoproteomic platform to discover small molecule drugs against traditionally undruggable targets across oncology, immunology, and neurology.
BridGene Biosciences (搜索) has raised $28 million in Series B+ financing to accelerate clinical development of its lead oncology candidate BGC-515, a covalent TEAD (搜索) inhibitor targeting solid tumors. The funding round was led by Bayland Capital (搜索), with participation from GTJA Investment Group (搜索), Proxima Ventures (搜索), and existing investors Lapam Capital (搜索) and Grains Valley Venture Capital (搜索).
The San Jose-based biotechnology company announced on October 16, 2025, that proceeds will primarily support advancing BGC-515 through ongoing clinical development toward Phase 2 trials. The funding will also enable the company's second program to enter clinical testing in 2027 and accelerate development of additional programs across oncology and autoimmune diseases.
Advancing Novel TEAD Inhibition Strategy
BGC-515 represents BridGene's lead program targeting TEAD (搜索) (TEA Domain Transcription Factor), a traditionally challenging target in oncology drug development. The covalent inhibitor is currently in clinical development for solid tumors, addressing a significant unmet medical need in cancer treatment.
"Our recent financing provides important resources to advance our lead program, BGC-515, a covalent TEAD (搜索) inhibitor, through Phase 2 clinical development," said Ping Cao, Ph.D., CEO and co-founder of BridGene Biosciences (搜索). "This funding will also enable us to progress additional pipeline programs toward the clinic and further expand the reach of our IMTAC™ chemoproteomic platform through strategic collaborations, as we continue to translate our discoveries into transformative therapies for patients."
Proprietary Platform Enables Undruggable Target Discovery
BridGene's approach centers on its proprietary IMTAC™ (Isobaric Mass-Tagged Affinity Characterization) chemoproteomic platform, which screens covalent small molecules against the entire proteome in live cells to identify novel binding sites and drug candidates for high-value targets. This technology enables the company to pursue traditionally undruggable targets across multiple therapeutic areas.
The financing will enhance BridGene's capacity to expand strategic collaborations and further validate the broad applicability of the IMTAC™ platform across oncology, immunology, and neurology. The company's approach integrates deep chemical biology with translational insight to unlock new therapeutic opportunities.
Strong Investor Confidence in Platform Technology
Yuexing Su, Founding Partner of Bayland Capital (搜索), expressed confidence in BridGene's differentiated approach to drug discovery. "BridGene's IMTAC™ platform represents a powerful and differentiated approach to drug discovery, enabling the company to discover small molecules against traditionally undruggable targets," Su said. "With a growing pipeline led by the covalent TEAD (搜索) inhibitor BGC-515 and multiple follow-on programs across oncology and autoimmune diseases, we believe BridGene is well positioned to deliver transformative therapies to patients and generate substantial value in the biopharmaceutical field."
Expanding Pipeline and Strategic Focus
Beyond BGC-515, BridGene is advancing a diversified pipeline with additional programs in oncology and autoimmune diseases. The company's second program is expected to enter clinical development in 2027, supported by the current financing round.
The funding positions BridGene to leverage its chemoproteomic platform for broader therapeutic applications while maintaining focus on translating discoveries into transformative medicines for patients with significant unmet medical needs across multiple disease areas.